Merck's Q1 2022 earnings call highlighted robust growth, particularly in KEYTRUDA and GARDASIL, with record revenue and earnings.  Management expressed confidence in their strategic priorities and pipeline advancements, including the expansion of KEYTRUDA into earlier lines of therapy and the increased supply of GARDASIL.  The call also emphasized the company's focus on long-term value creation and continued business development efforts.
[1]
